Tegoprazan is a novel, oral, potassium-competitive acid blocker (P-CAB).It reversibly inhibits the H+/K+-ATPase (proton pump) in a K+-competitive manner,providing rapid, potent, and long-lasting gastric acid suppression.
Approved Indications
Erosive esophagitis
Gastroesophageal reflux disease (GERD)
Gastric and duodenal ulcers
Prevention of NSAID-induced gastric ulcers
Key Features
Fast onset of acid inhibition
Long duration of action
Once-daily oral administration
Effective in healing and maintenance of GERD/erosive esophagitis
Stable pharmacokinetics, no food effect
Applications
API, intermediates, reference standards for R&D, generic registration and commercial manufacturing.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
China [CN] 
Click enlarge Image